Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5173598 | 0.99 | LTA4H (0.60) | LTA4HNPC1RAB9AHRH3 | |
| SCHEMBL5176478 | 0.93 | DRD2 (0.60) | LTA4HNPC1RAB9AHRH3 | |
| SCHEMBL5174712 | 0.86 | RAB9A (0.76) | LTA4HNPC1RAB9AHRH3FAAH | |
| SCHEMBL5175861 | 0.84 | NPC1 (0.75) | LTA4HNPC1RAB9AHRH3FAAH | |
| SCHEMBL5175763 | 0.83 | S1PR5 (0.69) | LTA4HNPC1RAB9AHRH3FAAH | |
| SCHEMBL5175555 | 0.83 | LTA4H (0.68) | LTA4HHRH3ACHE | |
| SCHEMBL42207 | 0.82 | ACHE (0.67) | LTA4HBCHEACHE | |
| SCHEMBL23775592 | 0.82 | RAB9A (0.58) | LTA4HNPC1RAB9AHRH3ACHE | |
| SCHEMBL16176142 | 0.82 | RAB9A (0.66) | LTA4HNPC1RAB9AHRH3 | |
| SCHEMBL14562348 | 0.81 | LTA4H (0.55) | LTA4HNPC1RAB9AHRH3FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1868605-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105304-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | claimed |
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | claimed |
| EP-1868605-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105304-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | LTA4H, LTB4R, LTC4S | LTA4H 1/4885NPC1 1667/4885RAB9A 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.